Amgen will buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with the company’s $74 billion deal for Celgene by the end of 2019.
Top 200 Medicines Annual Report 2019: The king of medicines
Ankylosing Spondylitits, August 2019, Autoimmune Diseases, Biologics, Biosimilars, Blockbusters, Cervical Cancer, Classical Hodgkin Lymphoma, Crohn's Disease, Esophageal Cancer, Forecasts, Gastric Cancer, Head & Neck Cancer, Hepatocellular Carcinoma, Hidradenitis suppurativa, Issue Archives, Juvenile Idiopathic Arthritis, Market exclusivity, Melanoma, Merkel cell carcinoma, Metastatic Urothelial Carcinoma (mUC), Microsatellite instability-high (MSI-H) cancer, Monoclonal Antibodies, Non-Small Cell Lung Cancer (NSCLC), Plaque Psoriasis, Primary lediastinal large B-cell lymphoma, Product Launches, Psoriatic Arthritis, Renal Cell Carcinoma (RCC), Rheumatoid Arthritis, Therapeutics, Top 200 Medicines, Ulcerative Colitis, UveitisHumira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
LEO Pharma Inc announced the U.S. Food and Drug Administration expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. Additionally, the FDA approved Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension in the topical treatment of scalp and body plaque psoriasis in patients 12 years and older.
Bristol-Myers plans to divest Celgene’s psoriasis drug
Acquisitions, Analysts, Autoimmune Diseases, Autoimmune Disorders, Blockbusters, Business, Cancer, European Commission, Immunology, M&A, Plaque Psoriasis, Psoriasis, Shares, Stocks, Tyrosine Kinase 2 Inhibitors, U.S. Federal Trade Commission (FTC)Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.
The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.
Celgene Corporation announced results from the phase 3 STYLE study, which showed that Otezla (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment response at week 16 compared with placebo.
Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz (ixekizumab) and Tremfya (guselkumab) in adult patients with moderate-to-severe plaque psoriasis.
Special Feature – First Year After Launch: The specialties win again
Ankylosing Spondylitits, Antipsychotics, August 2017, Autoimmune Diseases, Biotech, Blockbusters, Breast Cancer, CDK 4/6 Inhibitors, First Year After Launch special feature, First-In-Class, Hepatitis C, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, New Drug Applicationa, New Molecular Entities, Plaque Psoriasis, Potential Blockbusters, Product Launches, Psoriatic Arthritis, Specialty Medicines, TherapeuticsJust like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.
Encouraging results were reported from UNVEIL, the first trial of patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy.
2016 Annual Report: Top 200 Medicines
Angiogenesis, August 2016, Autoimmune Diseases, Autoimmune Disorders, Biologics, Biosimilars, Breast Cancer, Cervical Cancer, Colorectal Cancer, Crohn's Disease, Diabetes, FDA, FDA/Regulatory, Hepatitis C, Inflammatory Diseases, Kidney Cancer, Launches, Lung Cancer, Monoclonal Antibodies, Oncology, Ovarian Cancer, Patents, Plaque Psoriasis, Product Launches, Psoriasis, Rheumatoid Arthritis, Sales, Special Reports, Therapeutics, Ulcerative ColitisAbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.